DocGo Inc.
No enriched coverage for $DCGO in the last 7 days.
No SEC Form 4 filings for $DCGO in the last 30 days.
See all $DCGO insider activity →DocGo secured up to $102M in term loans at SOFR+7.5% maturing in 2029, issued 4M warrants at $0.5039, and terminated an undrawn Citibank revolver. The financing aims to boost liquidity and support operations, including potential mergers, according to the company.
DocGo Inc. (DCGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. Amended and Restated Credit Agreement and Guaranty On October 1, 2026, Hicuity and Ambulnz (together, the "Borrowers"), DocGo, certain subsidiaries of Ambulnz as guarantors, the lenders from time to time party thereto (the "Le
FORT Robotics to go public via SPAC deal valued at $500M, trading as FROB. DocGo acquires Hicuity Health to expand virtual care. Lydonia acquires Incin.ai assets. DocGo reports Q2 2026 growth, expects $305M-$310M revenue for 2026.
Recent DCGO coverage spans earnings, corporate actions and financial news.
The new financing improves liquidity and supports merger-related needs, likely easing short-term funding pressure.
New senior debt increases leverage and may pressure the stock, while the warrant could dilute equity if exercised.
FORT Robotics to go public via SPAC deal valued at $500M, trading as FROB. DocGo acquires Hicuity Health to expand virtual care. Lydonia acquires Incin.ai assets. DocGo reports Q2 2026 growth, expects $305M-$310M revenue for 2026.
Guidance deterioration and margin pressure increase downside risk to the path toward breakeven, while acquisition-related synergy timing remains a gating variable.
The combination of weaker-than-expected Q2 results, materially worse EBITDA outlook, and a debt-structured acquisition likely keeps downside pressure elevated.
AlphAI scores every news story that mentions DCGO with an AI model for sentiment and relevance, and aggregates insider trades from DocGo Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DocGo secured up to $102M in term loans at SOFR+7.5% maturing in 2029, issued 4M warrants at $0.5039, and terminated an undrawn Citibank revolver. The financing aims to boost liquidity and support operations, including potential mergers, according to the company.
1 min readDocGo Inc. (DCGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. Amended and Restated Credit Agreement and Guaranty On October 1, 2026, Hicuity and Ambulnz (together, the "Borrowers"), DocGo, certain subsidiaries of Ambulnz as guarantors, the lenders from time to time party thereto (the "Le
2 min readFORT Robotics to go public via SPAC deal valued at $500M, trading as FROB. DocGo acquires Hicuity Health to expand virtual care. Lydonia acquires Incin.ai assets. DocGo reports Q2 2026 growth, expects $305M-$310M revenue for 2026.
2 min readDocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved
7 min readDocGo (DCGO) shares fell about 12.7% pre-open to $0.62 after its Q2 2026 results missed expectations. Adjusted loss per share was $0.16 vs $0.10 forecast, revenue was $73.4M vs $75.4M. DocGo cut full-year 2026 adjusted EBITDA guidance to a $17M to $22M loss and agreed to acquire Hicuity Health, largely via debt assumption and new financing.
4 min readDocGo (DCGO) shares rose 2.4% in after-hours to $0.727 after its Q2 2026 earnings release and a 5:00 p.m. ET management call. Analysts expected a 15-cent per-share loss versus a 21-cent loss a year earlier. DocGo also sought a short SEC 10-Q filing extension and reiterated no major operating changes, with prior FY2026 sales guidance raised and a $26M buyback extended.
5 min readDocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DocGo Announces Second Quarter 2026 Results Company Signs Definitive Agreement to Acquire Virtual Care Provider Hicuity Health, Perceptive Advisors Commits to New Term Loan Funding Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK,
6 min readDocGo Inc. (DCGO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. dcgo-20260616 0001822359 FALSE 0001822359 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie
3 min readStifel Nicolaus has lowered its price target for DocGo (NASDAQ:DCGO) to $2.50 from $4.00, while maintaining a "buy" rating, indicating a potential upside of 218%. Despite a Q4 revenue beat and raised 2026 revenue guidance of $290M–$310M, the company faces significant execution risk due to a large EPS miss, year-over-year revenue decline, and weak margins, with the stock currently trading around $0.79. DocGo is exploring strategic alternatives to push towards profitability.
4 min readHalper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DocGo Inc. (NASDAQ: DCGO) breached their fiduciary duties to long-term shareholders. The firm encourages current DocGo shareholders to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or the return of funds to the company. The investigation aims to enhance shareholder value through improved company policies and oversight.
2 min read
